NuVision to Deploy Masimo SET®, Root® with
Radical-7®, NomoLine® Capnography, and Patient SafetyNet™ at Four
Locations
Masimo (NASDAQ: MASI) announced today that NuVision
Management Healthcare Consulting Company, a pediatric and adult
healthcare consulting company, is adopting a comprehensive variety
of Masimo technologies at its three pediatric care facilities in
New Jersey and Florida, including Voorhees Pediatric (121 beds),
Weisman Children’s Rehabilitation Hospital (18 beds), and
Plantation Kidz Korner (95 beds), as well as at a fourth,
adult-care location, Clark Nursing and Rehabilitation Center (144
beds).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190528005144/en/
Masimo Root® Patient Monitoring and
Connectivity Platform (Photo: Business Wire)
Pat Budo, Director of the Pediatric Complex Care Association
(PCCA), said, “NuVision is the latest member of the Pediatric
Complex Care Association to install Masimo technology. They join a
large number of current PCCA members in utilizing this technology
to support children with medical complexity. Both NuVision and
Masimo share our vision of promoting excellence across the
continuum of care for these extraordinary children.”
At every medically complex patient’s bedside at the four
locations, NuVision is installing Masimo Root® Patient Monitoring
and Connectivity Hubs equipped with Radical-7® Pulse CO-Oximeters®,
allowing patients to be monitored using Masimo SET® Measure-through
Motion and Low Perfusion™ pulse oximetry, in addition to a variety
of other rainbow SET™ parameters. NomoLine® capnography, available
as a MOC-9® expansion module for Root, will be used to support the
management of children on ventilators. Data from the ventilators
will also be available on Root, via Masimo Iris® third-party
connectivity, an integration NuVision is planning to implement this
summer.
Masimo Patient SafetyNet™, a supplemental remote monitoring and
clinician notification system, will allow clinicians to view
monitoring data for all beds from central view stations. When
changes occur in measured values that may indicate deterioration in
a patient’s condition, Patient SafetyNet automatically sends
wireless alerts directly to clinicians, wherever they may be,
allowing them to respond quickly and efficiently to potential
changes in patient status. Facilitated by Patient SafetyNet, all of
the data captured by Root and devices connected to it will be
transferred automatically to patient electronic medical records
(EMRs) – including monitoring data, vital signs, and
clinician-initiated early warning scores using the PEWS (pediatric
early warning score) protocol, which NuVision plans to start using
later this year as another way to help clinicians identify changes
in patient condition.
“These systems and technologies have been a great addition to
our organizations,” said Trish Cunningham, RRT, Clinical Director
of Respiratory Care at Voorhees Pediatric Facility and Weisman
Children’s Rehabilitation Hospital. “We are already noticing
improvements in patient care and are excited about the upcoming
integrations and capabilities.”
Masimo Root is a powerful, expandable bedside platform that
integrates an array of technologies, devices (such as Radical-7 and
the wearable Radius-7®), and systems to provide multimodal
monitoring and connectivity solutions – in a single,
clinician-centric hub. Root’s plug-and-play expansion capabilities
allow clinicians to simplify patient monitoring by bringing
together advanced rainbow SET Pulse CO-Oximetry, brain function
monitoring, regional oximetry, capnography, third-party devices,
and vital signs measurements on an easy-to-interpret, customizable
display, empowering clinicians with important information for
making patient assessments.
Mike Rosiak, Chief Operating Officer of Weisman Children’s
Rehabilitation Hospital and Voorhees Pediatric Facility said,
“Masimo’s Root and Patient SafetyNet medical systems will help us
to provide the best care for our medically fragile children and
enable them to reach their full potential.”
Jon Coleman, President of Worldwide Sales, Professional
Services, and Medical Affairs, Masimo, said, “We are proud to
partner with NuVision and bring the benefits of our innovative,
versatile, and proven medical technologies and connectivity
solutions to these particularly vulnerable patients. We look
forward to helping clinicians improve patient outcomes and the
lives of families with medically fragile children.”
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response activations, ICU
transfers, and costs.4-6 Masimo SET® is estimated to be used on
more than 100 million patients in leading hospitals and other
healthcare settings around the world,7 and is the primary pulse
oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S.
News and World Report Best Hospitals Honor Roll.8 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET™
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97™. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway™, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Doctella™. Additional information about
Masimo and its products may be found at www.masimo.com. Published
clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse
oximetry and the benefits of Masimo SET® can be found on our
website at http://www.masimo.com. Comparative studies include
independent and objective studies which are comprised of abstracts
presented at scientific meetings and peer-reviewed journal
articles.
- Castillo A et al. Prevention of
Retinopathy of Prematurity in Preterm Infants through Changes in
Clinical Practice and SpO2 Technology. Acta Paediatr. 2011
Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of
pulse oximetry screening on the detection of duct dependent
congenital heart disease: a Swedish prospective screening study in
39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer AH et al. Impact of pulse
oximetry surveillance on rescue events and intensive care unit
transfers: a before-and-after concurrence study. Anesthesiology.
2010:112(2):282-287.
- Taenzer A et al. Postoperative
Monitoring – The Dartmouth Experience. Anesthesia Patient Safety
Foundation Newsletter. Spring-Summer 2012.
- McGrath SP et al. Surveillance
Monitoring Management for General Care Units: Strategy, Design, and
Implementation. The Joint Commission Journal on Quality and Patient
Safety. 2016 Jul;42(7):293-302.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SET®, rainbow SET™,
Root® with Radical-7®, NomoLine®, and Patient SafetyNet™. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SET®, rainbow SET, Root with
Radical-7, NomoLine, and Patient SafetyNet, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190528005144/en/
Media:MasimoEvan Lamb949-396-3376elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024